Description
OTSSP167 inhibits maternal embryonic leucine zipper kinase (MELK). MELK has been identified as a possible therapeutic target for breast cancer, and is highly upregulated in other cancer types. OTSSP167 suppresses mammosphere formation of breast cancer cells and tumor growth in xenograft studies. In epithelial ovarian cancer, treatment with OTSSP167 reduced cell proliferation through G2/M cell cycle arrest resulting in apoptosis, even in cisplatin-resistant and paclitaxel-resistant cancer cells. TEST!!!!!!